Business Wire

Samsung Bioepis Settles Patent Disputes with AbbVie, Clearing the Way for the Commercialization of SB5 (Adalimumab) in All Approved Markets Worldwide

Jaa

Samsung Bioepis Co., Ltd. today announced that it has signed a licensing agreement with AbbVie Inc., settling all pending patent litigation between the two companies and clearing the way for the worldwide commercialization of Samsung Bioepis’ SB5, a biosimilar referencing Humira® i (adalimumab), in all approved markets worldwide. Under the terms of the agreement, SB5 may be launched in Europe from October 16, 2018 onwards and, if approved, in the United States (US) from June 30, 2023 onwards.

SB5 has been granted marketing authorization by the European Commission (EC) as IMRALDI®, and will be commercialized in Europe by Biogen. In the US, SB5 has not yet received regulatory approval.

“We welcome this agreement which clears the way for SB5 in approved markets across the world. The earliest impact of this agreement will likely be seen in Europe, where SB5 has already been approved and is expected to become our third TNF inhibitor available in the region,” said Jaywoo Kim, Senior Vice President and Head of the Commercial Division at Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry's strongest biosimilar pipelines, so that more patients and healthcare systems across the world may benefit from biosimilars.”

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

i Humira ® is a registered trademark of AbbVie Inc.

Contact information

MEDIA CONTACT:
Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer21.6.2018 14:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival in patients treated with trifluridine/tipiracil and best supportive care (BSC) was 5.7 months as compared to 3.6 months when treated with placebo and BSC, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by PFS, a key secondary endpoint, was reduced by 43% (HR: 0.57). The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer (CRC), with mainly hematological adverse events reported. “The results presented to

SimScale Announces a Preview Program of FDS for Simulation of Fire Scenarios in Buildings21.6.2018 13:49Tiedote

SimScale (“SimScale”), the provider of the world’s first cloud-based engineering simulation solution, today announced the launch of the Fire Dynamics Simulator (FDS) explorative preview program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005523/en/ Fire Dynamics Simulator (FDS) is a solver developed by the National Institute of Standards and Technology (NIST) of the United States Department of Commerce, in cooperation with VTT Technical Research Centre of Finland. Throughout its development, FDS has been aimed at solving practical fire problems in fire protection engineering, while at the same time providing a tool to study fundamental fire dynamics and combustion. The preview program is a response to the request of many customers to combine the maturity and reliability of FDS for modeling fire and smoke with the convenience and scalability of SimScale’s cloud-based simulation infrastructure. Most of these requests

Warehouse TERRADA Forms a Three-Party Partnership with Yokohama University of Art and Design and PALAZZO SPINELLI, an Italian Institute for Art and Restoration21.6.2018 12:00Tiedote

Warehouse TERRADA formed a three-party partnership with Tokiwamatsu Gakuen’s Yokohama University of Art and Design and PALAZZO SPINELLI ISTITUTO PER L’ARTE E IL RESTAURO, an institute for art and restoration located in Florence, Italy, concerning the restoration and preservation of cultural heritage in Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005372/en/ From left) Emanuele Amodei, President of Palazzo Spinelli / Yasuyuki Korekawa, Operating officer of Warehouse TERRADA / Nobuaki Okamoto, Chairman of the Board of Directors, Tokiwamatsu Gakuen and President, Yokohama University of Art and Design (Photo: Business Wire) Warehouse TERRADA has always considered it to be important to educate future professionals involved in the restoration and preservation of artworks and craftworks. We have made a wide-ranging proactive effort in this field, such as by launching a collaborative course in art restoration and pres

Further STAC Approval for Smiths Detection’s Checkpoint.Evoplus21.6.2018 11:00Tiedote

The latest version of Smiths Detection’s Checkpoint.Evoplus software has been certified by STAC for use at French airports. Version 2.2. has followed in the footsteps of 2.1, which was the first ever solution for multiplexed image analysis to receive official approval from the French civil aviation authority technical centre. An advanced screening and management platform, Checkpoint.Evoplus is designed to increase passenger throughput; optimise resources; reduce operational costs; and raise security levels. “Both versions of Checkpoint.Evoplus have now gained STAC certification –further approval for a very innovative platform, which continues to set the standards for checkpoint management software,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “It holds the key to ensuring that checkpoints can reach their full potential by delivering the highest levels of security and also significant operational advances.” Checkpoint.Evoplus transforms a collection of i

Presidentti Obama Nordic Business Forumiin Helsinkiin21.6.2018 10:59Tiedote

Yhdysvaltain entinen presidentti Barack Obama on kiinnitetty puhumaan Nordic Business Forumissa, joka järjestetään 26.-27.9.2018 Helsingissä. Presidentti Obama tulee päättämään kaksipäiväisen tapahtuman. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180621005425/fi/ Europe’s leading business and leadership conference brings President Obama to Helsinki, Finland to speak to business executives and owners. (Photo: Business Wire) Aslak de Silva, Nordic Business Forumin toimitusjohtaja: “Tämä on meille valtava kunnia, ja myös hieno mahdollisuus ja tilaisuus asiakkaillemme sekä Suomelle ja Pohjoismaille.” Hans-Peter Siefen, Nordic Business Forum hallituksen puheenjohtaja ja perustajajäsen: “Todella hienoa saada presidentti Obama tapahtumamme pääpuhujaksi. Tapahtuman agenda on jo ennestään upea ja tämä on sille hieno kruunu. Varmasti merkittävin puhujakiinnityksemme koskaan. Pari muutakin hyvin teemaspesifiä puhujaa on vielä tu

Mori Building and teamLab Launch Unprecedented Digital Art Museum21.6.2018 05:00Tiedote

“MORI Building DIGITAL ART MUSEUM: teamLab Borderless,” an unprecedented digital art museum — jointly created and operated by Mori Building Co., Ltd, a leading urban landscape developer, and teamLab, a world-leading digital art collective — opened today, the two organizers announced. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005005/en/ Toshiyuki Inoko, Founder of teamLab (Photo: Business Wire) The digital art museum features approximately 50 interactive artworks, some completely new, in a huge 10,000m² area with five zones. The interactive artworks have no borders separating them from the other works. Some extend beyond their installation rooms and into the corridors, some overlap with other works and some even fuse with other works. Since there are no boundaries, the immersive works keep the boundaries between people in a state of continuous flux. Visitors physically enter and explore the works as well as experie

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme